1. Home
  2. PEBO vs RVMDW Comparison

PEBO vs RVMDW Comparison

Compare PEBO & RVMDW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PEBO
  • RVMDW
  • Stock Information
  • Founded
  • PEBO 1902
  • RVMDW N/A
  • Country
  • PEBO United States
  • RVMDW United States
  • Employees
  • PEBO N/A
  • RVMDW 490
  • Industry
  • PEBO Major Banks
  • RVMDW
  • Sector
  • PEBO Finance
  • RVMDW
  • Exchange
  • PEBO Nasdaq
  • RVMDW Nasdaq
  • Market Cap
  • PEBO N/A
  • RVMDW N/A
  • IPO Year
  • PEBO N/A
  • RVMDW N/A
  • Fundamental
  • Price
  • PEBO $31.90
  • RVMDW $0.24
  • Analyst Decision
  • PEBO Hold
  • RVMDW
  • Analyst Count
  • PEBO 3
  • RVMDW 0
  • Target Price
  • PEBO $35.33
  • RVMDW N/A
  • AVG Volume (30 Days)
  • PEBO 101.1K
  • RVMDW N/A
  • Earning Date
  • PEBO 01-21-2025
  • RVMDW N/A
  • Dividend Yield
  • PEBO 4.92%
  • RVMDW N/A
  • EPS Growth
  • PEBO 3.01
  • RVMDW N/A
  • EPS
  • PEBO 3.51
  • RVMDW N/A
  • Revenue
  • PEBO $428,740,000.00
  • RVMDW N/A
  • Revenue This Year
  • PEBO N/A
  • RVMDW N/A
  • Revenue Next Year
  • PEBO $1.08
  • RVMDW N/A
  • P/E Ratio
  • PEBO $9.27
  • RVMDW N/A
  • Revenue Growth
  • PEBO 10.64
  • RVMDW N/A
  • 52 Week Low
  • PEBO $26.74
  • RVMDW N/A
  • 52 Week High
  • PEBO $37.07
  • RVMDW N/A
  • Technical
  • Relative Strength Index (RSI)
  • PEBO 32.41
  • RVMDW N/A
  • Support Level
  • PEBO $34.24
  • RVMDW N/A
  • Resistance Level
  • PEBO $35.07
  • RVMDW N/A
  • Average True Range (ATR)
  • PEBO 0.88
  • RVMDW 0.00
  • MACD
  • PEBO -0.38
  • RVMDW 0.00
  • Stochastic Oscillator
  • PEBO 2.78
  • RVMDW 0.00

About RVMDW Revolution Medicines Inc. Warrant

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Share on Social Networks: